Introduction
Cytotoxic drugs used in cancer treatment typically have a narrow therapeutic window, with severe toxicity caused by their unspecific mode of action affecting rapidly dividing cells on one side, and the need for sufficiently high doses for efficacy on the other side (Gurney, 1996) . Paclitaxel is a cytotoxic which is wildly used in different cancer types. It enhances and stabilizes the polymerization of microtubules, leading to clinically relevant toxicity, especially dose-limiting neutropenia. This frequent and severe adverse event is caused by the cytotoxic effect on proliferating cells, particularly bone marrow progenitor cells, leading to potentially life-threatening infections (Mitchison, 2012) . Neutropenia caused by paclitaxel-containing combination therapies can even be cumulative, meaning a worsening of neutropenia over the repeated treatment cycles (Huizing, et al., 1997) . In addition, the pharmacokinetics (PK) of paclitaxel administered in a formulation with Cremophor EL is nonlinear, schedule-dependent (e.g. influence of infusion duration) and exhibits high interindividual variability. The time of paclitaxel plasma concentration above the threshold of 0.05 µmol/L (TC>0.05) was found to be a relevant PK exposure surrogate for toxicity (Gianni et al., 1995; Ohtsu et al., 1995; Huizing, et al., 1997; Lichtman et al., 2006; and efficacy (Huizing, et al., 1997; , i.e.
26-31 h (Joerger et al., 2012) . The combination of narrow therapeutic window and high interindividual variability highly favors dose individualization based on therapeutic drug monitoring.
Currently the dose of paclitaxel is adjusted by body surface area (BSA), found to be influential on paclitaxel PK (Smorenburg et al., 2003) , but not by other relevant factors such as organ (dys)function or age (Mielke et al., 2007) . Furthermore, paclitaxel is typically part of a combination therapy with carboor cisplatin displaying toxic effects on the haematopoietic system as well. In summary, individualized therapy of paclitaxel combination therapy is needed to balance toxicity and efficacy.
Pharmacokinetic/pharmacodynamic (PK/PD) modelling and simulation is suggested as a tool to improve the dosing of paclitaxel by reducing toxicity without compromising efficacy given the complex PK of paclitaxel and the combination therapy (Joerger et al., 2016) . Based on a pooled PK/PD analysis from several clinical trials including different cancer types, a PK/PD model to characterize paclitaxel plasma concentrations (PK) and resulting neutropenia (PD) was developed (Joerger et al., 2012) . The PK was described by a 3 compartment model including nonlinear distribution and elimination, while for the PD the neutropenia model structure developed by Friberg et al. (Friberg et al., 2002) was applied for paclitaxel-associated neutropenia. The PK/PD model was then utilized to develop a dose This article has not been copyedited and formatted. The final version may differ from this version.
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JPET #240309 -8 -individualization algorithm, considering different covariates (BSA, age, sex) as well as target drug exposure (TC>0.05) and toxicity (grade of neutropenia) from the previous cycle. Next, the dosing algorithm was applied in the CEPAC-TDM trial (CESAR study of paclitaxel therapeutic drug monitoring (Joerger et al., 2016) ). The aim of this prospective, multicenter, randomized, controlled clinical study was to investigate whether therapeutic drug monitoring and target-concentration intervention, based on sparse sampling, of paclitaxel was able to reduce toxicity while maintaining efficacy compared to standard BSAbased dosing of paclitaxel. The results showed that the exposure target of the TC>0.05 (26-31 h) was not met in more than 50% patients, and no significant improvement of grade 4 neutropenia was achieved for patients in the experimental arm . Nevertheless, paclitaxel-related neuropathy was substantially improved. With this clinical trial, an important step towards an optimal and individualized dosing of paclitaxel in combination with cis-/carboplatin was done. Reasons for the lack of improvement of paclitaxel-related neutropenia may include suboptimal PK and PD models used for the paclitaxel dosing algorithm as used in the CEPAC-TDM trial. Thus, further improvement in the models and the dosing algorithm are needed to reduce the toxic burden for the patients.
The aim of the present study was to investigate the appropriateness of the original PK/PD model for the data from the CEPAC-TDM trial and detect potential model misspecifications. Furthermore, the PK/PD model should be optimized to be able to adequately capture cumulative neutropenia after repeated treatment cycles of paclitaxel in combination with cis-/carboplatin. The optimized model shall consider physiological plausibility to be able to simulate different dose optimization scenarios of the paclitaxel combination chemotherapy.
This article has not been copyedited and formatted. The final version may differ from this version. 
Materials and Methods

Clinical data
To evaluate the previously developed PK/PD model, data from the CEPAC-TDM study (Joerger et al., 2016) carried out in accordance with the Declaration of Helsinki and approved by the Institutional Review Boards were use. Briefly, patients with newly diagnosed advanced non-small cell lung cancer (NSCLC) were treated with paclitaxel (3 h intravenous infusion) in combination with either cis-or carboplatin every 3 weeks for up to 6 cycles. 182 patients (740 treatment cycles in total) in the conventional study arm received the standard dose of paclitaxel (200 mg/m²), while 183 patients (720 treatment cycles in total) in the experimental study arm received a paclitaxel dose adapted to sex, age and BSA for the first treatment cycle. In the following cycles, the dose for these patients was further adapted based on i) the experienced grade of neutropenia and ii) the paclitaxel exposure, expressed as TC>0.05 both of the previous cycle. PK samples were only taken from patients in the experimental arm, once per cycle (approx. 24 h (16-30 h) after start of infusion), since only here the dose adaptation based on TC>0.05 was performed. TC>0.05 was determined by post-hoc estimation with the original PK model in NONMEM. PD samples (neutrophil measurements) were taken in both arms at baseline, on day 1 and day 15±2 in each cycle and finally at the end of treatment visit. Paclitaxel concentrations were determined by liquidchromatography and UV detection (lower limit of quantification: 0.015 mg/L (=0.017 µmol/L); recovery: 90.6±9.63; overall precision: <10%) (Zufía López et al., 2006) . Neutrophil concentrations were measured in routine clinical chemistry analysis at each study side.
The low number of measurements below the lower limit of quantification (PK: 0.30%, PD: 0.40%) as well as missing samples (PK: 8.61%; PD of conventional arm: 11.4%; of experimental arm: 9.25%) were assumed to be missing completely at random and removed from the subsequent PK/PD analysis. For these, primarily data from the experimental arm were considered, since only these patients underwent paclitaxel PK sampling. Only for evaluation of the newly developed PK/PD model, dosing information, neutrophil concentration measurements and covariate data from the conventional arm were used. A summary of patient characteristics can be found in (Joerger et al., 2016) and a summary of the entire modelling and simulation workflow can be found in the Supplemental Figure 1 .
Original PK model and external evaluation
This article has not been copyedited and formatted. The final version may differ from this version.
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-10 -The analysis was based on a previously published PK/PD model ("original model") (Joerger et al., 2012) , which was also used to develop the CEPAC TDM dosing algorithm. The PK of paclitaxel was described by a three-compartment model (Figure 1 , upper left panel) with nonlinear distribution to the first peripheral compartment and non-linear elimination. BSA, sex, age and total bilirubin concentration (BILI) were implemented as covariates on the maximum elimination capacity (VMEL) using power relations. An exponential model was assumed for interindividual, interoccasion and residual variability.
This PK model was externally evaluated using the data from the experimental arm of the CEPAC-TDM study. For this purpose, post-hoc estimation with the original PK model was performed to obtain individual PK parameters (empirical Bayesian estimates, EBE) and the individually predicted paclitaxel concentration-time profiles. Model performance was then evaluated by basic goodness-of-fit plots, shrinkage (Savic and Karlsson, 2009 ) and comparing 1000 simulations with the study data in predictioncorrected visual predictive checks (pcVPC) (Bergstrand et al., 2011) . As in the original model the firstorder conditional estimation method with interaction was used for all PK analyses.
PK model optimization using prior information
To refine the PK model for the population in the CEPAC-TDM study, the final PK parameter estimates and their precision (diagonal elements of the variance-covariance matrix), retrieved from the original PK model, were implemented in the maximum a posteriori (MAP) Bayesian approach (originally referred to as frequentist approach) as prior information using the Normal-InverseWishart distribution (Gisleskog et al., 2002) . Interoccasion variability was not re-estimated but assumed to be the same as originally estimated, since only one PK measurement per cycle (= occasion) was available. The degrees of freedom for estimating interindividual variability were calculated as described in (Bauer, 2014) while for the residual variability 1000 was chosen as the lowest number allowing stable estimation.
The optimized PK parameters were compared with the original ones at the population and individual level. A bootstrap analysis (Efron and Tibshirani, 1986 ) (1000 bootstrap datasets) was performed to evaluate parameter precision and the 95% confidence intervals were compared as well as population parameter estimates. Confidence intervals of the original model were calculated based on the standard error, retrieved from the original model, assuming normal distribution. To evaluate improvements of the model prediction, a pcVPC was generated (n=1000 simulations).
This article has not been copyedited and formatted. The final version may differ from this version. (Sheiner and Beal, 1981) :
in which Pi,o,original and Pi,o,optimized were the EBEs and exposure parameters (TC>0.05 and area under the curve (AUC)) of individual "i" at occasion "o" (if interoccasion variability was applicable) based on the original and the optimized model, respectively; RPEp,i,o was the relative prediction error between the original and the optimized parameter, for each model parameter "p", MRPEp was the median relative prediction error indicating bias and MARPEp was the absolute (unsigned) value of the relative prediction error expressing imprecision for each parameter taking as reference the optimized parameters.
Original PK/PD model and external evaluation
The neutrophil concentrations in (Joerger et al., 2012) were described by the semi-mechanistic neutropenia PK/PD model developed by Friberg et al. For the sequential PK/PD analysis EBEs of the optimized population PK parameters and the associated individual concentration-time profiles of paclitaxel were used to inform the drug effect (Edrug) of the PK/PD model by introducing a linear PK/PD relationship with slope factor (SL). This method implies a cytostatic drug effect if Edrug≤1 and a cytotoxic effect if Edrug>1, since the proliferating rate constant kprol was multiplied by 1-Edrug.
In the Friberg et al. model the granulopoiesis was described by a chain of 5 compartments, of which the first represents the proliferating cells (Prol). These cells replicate (with the proliferating rate constant kprol) and then mature and differentiate via a chain of n=3 transit compartments with a transition rate constant ktr obtained from the mean maturation time (MMT): ktr=MMT/(number of transitions), until they are circulating neutrophil (Circ) that can be measured in the blood. Finally, the circulating neutrophils can be eliminated by a first-order process. To gain homeostasis of the system, this elimination rate constant was assumed to be equal to kprol and ktr. At the same time, kprol was influenced by Edrug in an inhibitory manner and a feedback mechanism (FB) responsible for the recovery after drug
administration. An exponential model was assumed for interindividual variability on SL, MMT and for residual variability.
This article has not been copyedited and formatted. The final version may differ from this version. Briefly: Model A ( Fig 1A) (based on Bender et al., 2012) , was originally developed to describe thrombocytopenia in patients treated with trastuzumab emtansine. In this model, the circulating cells (originally thrombocytes, here neutrophils) at baseline (BASEtot(t0)) were assumed to belong to two different subpopulations (BASE1 and BASE2). BASE2 was affected by a second time-dependent drug effect (Edrug2), leading to a reduction of the total baseline over time (BASEtot(t)), which was the target value of the feedback mechanism. While originally the average concentration of trastuzumab emtansine was determining the extent of this second drug effect Edrug2, here TC>0.05 of paclitaxel of each cycle was assumed to drive this effect. Additionally to the PD parameters estimated in the original model (MMT, γ, SL), the fraction of BASEtot(t0) not affected by the second drug effect (frB), as well as the depletion rate constant of Edrug2 on BASE2 (kdepl) were estimated. For physiological plausibility, Model C ( Fig 1C) was additionally newly developed that mimicked also slowly replicating pluripotent stem cells in the bone marrow as a prior additional compartment ("Stem")
Model B (Fig
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-13 -in the chain of granulopoiesis. Their proliferation was controlled by a different proliferation rate constant (kstem). Model C was described by the following set of ordinary differential equations:
in which Stem, Prol, Transit1, Transit2, Transit3 and Circ represent different stages of granulopoiesis.
Both proliferation rate constants (kprol and kstem) were affected by the same PD parameter (SL) and feedback mechanism. To ensure homeostasis of the system without therapy, kprol was estimated as a fraction ftr of the transition rate constant ktr:
Hence, ftr is the fraction of kprol (ftr) and kstem (i.e. the remaining fraction (1-ftr)) of the sum of both input processes for Prol -and due to equilibration -the corresponding fractions of ktr. Thus, ftr determines the ratio between kstem and kprol (kstem/kprol=(1-ftr)/ftr). As approximations, if ftr is estimated >0.5, then kstem becomes smaller than kprol; oppositely, if ftr=1, then kstem=0 which would result in the original Friberg et al. model . This parametrization enabled that ktr could still be computed as in the original Friberg et al. model, by estimating MMT.
To describe baseline neutrophil concentrations, individual pretreatment concentrations were used allowing for residual variability ("baseline method 2" (Dansirikul et al., 2008) ). This individual baseline value (Circ0) was also the initial condition for all PD compartments of the differential equations in all PK/PD models (i.e. Stem(t0)=Prol(t0)=Transit1(t0)=Transit2(t0) =Transit3(t0)=Circ(t0)=Circ0), except in An exponential model was applied for the interindividual variability as well as for the residual variability.
First-order conditional estimation method with interaction was used for the 3 models.
Comparing Model A-C: model evaluation and model performance
Model evaluation and selection was based on parameter precision (relative standard error, RSE), condition number (ratio of highest to lowest eigenvalue of the correlation matrix), goodness-of-fit plots of individual predictions, population predictions and weighted residuals as well as on pcVPCs. Further, the Akaike Information Criterion (AIC=OFV+2•k; in which OFV is the objective function value and k is the number of model parameter estimates) was used, if models were not nested. In addition, physiological plausibility was considered to ensure reliable extrapolations for subsequent simulations of different dosing scenarios.
Deterministic simulations were performed to explore the performance of Model A-C for a typical patient (male, 56 years, total bilirubin concentration: 7 µmol/L, BSA: 1.8 m², baseline neutrophil concentration:
6.48•10 9 cells/L (= median baseline of males, experimental arm)) undergoing 3-weekly dosing of 185 mg/m² for 6 cycles using the typical parameter estimates of each model. Cell concentrations not only in the circulating cell compartment, but for all compartments were explored. For Model A, the second drug effect was either assumed to be active only until the end of the last cycle (3 weeks after the last dose administration) or to continue beyond the end of observation period.
The relative change of the highest and the lowest neutrophil concentration (nadir) from the 1 st to the 6 th cycle of each model was calculated based on this deterministic simulation and used to quantify cumulative neutropenia:
Relative change of maximum value, % = 100 − (
Relative change of nadir value, % = 100 − ( -15 -platinum-based drugs, two published structural and covariate PK models (de Jongh et al., 2004; Lindauer et al., 2010) were integrated. Since no drug concentration measurements were available, variability was neglected. Thus, the typical concentration time-profiles of carbo-and cisplatin, respectively, were retrieved and these population predictions were used to estimate two additional slope factors for carbo-and cisplatin. An additive drug effect was assumed for the combination therapy.
in which SLPlatin and CPlatin(t) are the slope factor and the plasma concentration at time t of the coadministered platinum-based drugs, respectively.
This combination PK/PD model was evaluated as described for Model A-C. In addition, as described for the original PK/PD model, an external model evaluation was performed using the data from the conventional study arm. For this step, a pcVPC was generated, simulating 1000 datasets with the combination PK/PD model (in a simultaneous PK/PD analysis) considering interindividual variability in the PK and PD parameters.
Software for data analysis
All modelling and simulation activities were performed in NONMEM (version 7.3; Icon Development 
Results
Data analysis: CEPAC-TDM Study
The two different dosing strategies of the two study arms led to a higher median paclitaxel dose of 315 mg in the conventional arm (range: 205-438 mg) vs 270 mg (range: 111-505 mg) in the experimental arm. In addition to paclitaxel, patients received a platinum-based drug, primarily carboplatin (149 vs 33 in the conventional and 153 vs 30 in experimental arm, respectively). From those 63 patient in the cisplatin group, 9 were switched to carboplatin co-treatment during the therapy, due to cisplatin-related toxicity.
A total of 658 paclitaxel PK samples were obtained from the experimental arm (no PK measurements available from the conventional arm), while 1635 and 1639 PD measurements were available from the conventional and experimental arm, respectively.
External PK model evaluation and optimization using prior information
Paclitaxel concentrations from the CEPAC-TDM clinical trial were used to evaluate the original PK model for its applicability to the present data. This external PK model evaluation showed a good prediction of the individual measurements (Supplemental Figure 2) Figure 2A ), especially in the relevant target concentration range of 0.05 µmol/L.
To account for the observed misspecification and to improve the predictivity of the PK model, the MAP Bayesian approach (Gisleskog et al., 2002) was applied combining the original PK parameter estimates (Table 1, -17 -2 nd peripheral compartment (Q) (+9.5% and +7.7%, respectively), even though they were still within the 95% confidence interval of the original parameters. The higher estimates of V3 and Q translated into a larger paclitaxel distribution to the 2 nd peripheral compartment and a reduced distribution back to the central compartment. These, together with a lower elimination (due to increased KmEL) led to higher predicted paclitaxel concentrations, especially in the later phases of the concentration-time profile resulting in higher exposure. These changes in the PK parameters resulted in an improved description of the paclitaxel concentration time-profiles as illustrated in Figure 2B .
Aside from the population level, differences in the individual prediction resulting from the two PK parameter sets (original and optimized) were assessed by comparing their EBEs and individual exposure parameters ( Figure 2C ): For EBEs V3 showed the highest difference in the EBEs (MRPEp: -14.7%) while overall higher individual exposure estimates of TC>0.05 and AUC (MRPEp: -5.82% and -4.28%, respectively) were revealed for the optimized PK model.
External PK/PD model evaluation
Subsequently, the EBEs obtained with the optimized PK model were used to predict the individual PK concentration-time profiles, which eventually informed the PD response using the original PD parameters of the Friberg et al. model . This PK/PD model overpredicted the neutrophil concentrations (thus, underpredicted severity of neutropenia) during the whole observed period (pcVPC, Figure 3A) ; overprediction was already present for day 15 values in the 1 st cycle, and increased for the measurements of day 1 and day 15 over the cycles. While the cumulative neutropenia led to decreasing neutrophil concentrations on day 1 and 15 over the cycles, the model predicted increasing neutrophil concentrations on day 15 instead since the dose was reduced during therapy. This led to an increasing discrepancy between observed neutrophil data and model prediction over time.
PK/PD model optimization
To better describe cumulative neutropenia over repeated treatment cycles the PD part was optimized.
The performance and behavior of 3 different structural PK/PD models, two from literature (Model A and B, Figure 1A and B) and one newly developed for physiological plausibility (Model C, Figure 1C ), were evaluated.
Parameters of all models were estimated with high precision (RSE<15%) ( approximately 73% slower than in Prol. Interindividual variability on the MMT was negligible in the optimized PK/PD models, due to small estimates (coefficient of variation <10%) and high η-shrinkage (>50%).
The pcVPCs ( Figure 3B-D) showed that all 3 PK/PD models captured some of the observed pattern of cumulative neutropenia, but to a different extent. Model A and C described the observed neutrophil concentrations similarly well compared to Model B, especially in the later cycles.
Further, Model C was not improved by implementation of an Emax model compared to a linear drug effect model. In addition, different baseline methods and variations in the number of transit compartments were explored but did not improve the model in terms of objective function value, parameter precision goodness-of-fit plots and pcVPCs.
Regarding the deterministic simulation with constant doses of 185 mg/m² for 6 cycles (Figure 4 ), Model A predicted approximately the same maximum value for the 1 st cycle (baseline) and the 2 nd cycle; thereafter, the relative change of maximum value over all 6 cycles was the highest (31.4%) comparing
Model A-C. The relative change of nadir value (36.5%) was in between Model B and C. Model B predicted the lowest degree of cumulative neutropenia (relative change of nadir and maximum value:
7.65% and 17.0%, respectively), despite the most significant initial relative change in the maximum value from the 1 st to the 2 nd cycle; afterwards the maximum value was not changing further. Model C predicted a relative change of the maximum value of 27.6% which was between Model A and B; at the same time, the highest cumulative neutropenia effect for the nadir value (relative change of the nadir value: 67.8%) was observed. This high degree of cumulative neutropenia resulted in grade 2 neutropenia for the 1 st cycle, grade 3 from the 2 nd and grade 4 from the 5 th cycle on. In summary, even though all models described the observed cumulative neutropenia, the deterministic simulation of Model C was the most plausible and the model performance was also superior regarding the AIC.
Differentiation between the effect of paclitaxel and the platinum-based drugs
Model C was further expanded to distinguish between the drug effect of paclitaxel and platinum-based drugs. Based on the pcVPCs (Figure 3E ), the performance was similar to Model C, nevertheless the AIC dropped 42.5 points. Parameters were estimated with sufficient precision (RSE<20%) for all parameters, but those of the slope factors slightly increased (RSE: 16.9%, 26.1%; Table 2 , right column).
The condition number (113) did not indicate an overparameterisation of the model. Estimated system PD parameters remained within the range of those of Model C. Only the drug effect of paclitaxel was reduced by 60.5% compared to Model C, given that the effect was now split into two effects, for paclitaxel and the platinum-based drugs. Interindividual variability on the slope factor of paclitaxel was increased compared to Model C. While the slope factor of carboplatin was estimated in a reasonable range, the This article has not been copyedited and formatted. The final version may differ from this version. Finally, the optimized PKPD platinum combination model, including separate drug effects for paclitaxel and the platinum-based drugs was used to predict the neutrophil concentration-time profiles of the conventional study arm of the CEPAC-TDM study (pcVPC, Figure 3F) . A good prediction of the median and 95 th percentile was achieved, although an underprediction of the low concentration-time profiles (5 th percentile) was visible but still predicted the same neutropenia grade.
Discussion
Due to the narrow therapeutic window and the high interindividual PK and PD variability of paclitaxel, model-based dose individualization can help to reduce toxicity without compromising efficacy, as in a first step shown for neuropathy in the CEPAC-TDM study (Joerger et al., 2016) but not for neutropenia.
To further improve therapy for patients suffering from severe neutropenia, we evaluated, optimized and expanded the PK/PD model on which the dosing algorithm for the CEPAC-TDM study was developed.
Thus, the Friberg et al. neutropenia PK/PD model was extended to describe cumulative neutropenia after repeated chemotherapy cycles in combination with cis-/carboplatin.
The individual PK predictions of the original model matched the paclitaxel concentrations measured in the CEPAC-TDM study well, due to the sparse sampling and the high interindividual variability in the model. However, an underprediction was observed when evaluating the population level, pointing towards suboptimal original PK parameter values for the investigated population. Since PK/PD modelling was undertaken sequentially, PK misspecifications may also affect PD. Therefore, PK model optimization was performed using the MAP Bayesian approach (Gisleskog et al., 2002) . The reestimated parameters described the paclitaxel concentrations in the terminal phase of the concentrationtime profile better by a faster distribution to the 2 nd peripheral compartment and slower elimination.
Further, the optimized PK parameter set predicted higher exposure for the population and the individuals. Overall, the re-estimated PK parameters were in line with parameters previously published (high volume of distribution (>100 L) (Gianni et al., 1995; van Zuylen et al., 2001) ; fast elimination (clearance >30 L/h) (Wiernik et al., 1987; van Zuylen et al., 2001) ) and improved the predictive performance. Thus, the re-estimated PK parameters were used for the following steps.
An external evaluation of the Friberg et al. neutropenia model was performed with two major findings:
First, overprediction of neutrophil concentrations at day 15, i.e. less toxic effect on neutrophils, already in the 1 st cycle, pointed towards the need of a higher slope factor. Second, cumulative neutropenia, which was not accounted for in the Friberg et al. model but is often seen in clinical practice after repeated cycles with cytotoxic drugs, but only rarely investigated. We hypothesized that this pattern was caused by bone marrow exhaustion (BME) due to the damage of early primitive bone marrow stem cells, such as pluripotent long-term haematopoietic stem cells (Mauch et al., 1995) . (comparable to G0 phase in cell cycle). Finally, a new model, Model C, was developed to implement the BME hypothesis by adding a stem cell compartment as first compartment in the maturation chain. In accordance with physiology, proliferation of the stem cells was slower (73%) but was affected by the same drug-and feedback effect as cells in Prol.
All three PK/PD models were successfully implemented and parameters were estimated with high precision. The slope factor of these models was estimated to be higher than in the original model, while high differences between them were observed but could not be compared across models due to differences in the implementation of the drug effect.
Cumulative neutropenia was described by all three models to a certain extent, however the potential for extrapolation of Model A and B may be limited. For Model A, the parameter estimate kdepl for the timedependent effect is specific for the treatment cycle length of the underlying data and predictions after the end of treatment strongly depend on the assumptions for the duration of Edrug2. For Model B, full recovery and equilibrium was reached very quickly after the last dose. Thus, an increased cycle length would reduce or let disappear the cumulative effect which is often experienced by oncologists who then empirically reduce dosing (as in conventional study arm). Model C, on the other hand, described cumulative neutropenia in a more semi-mechanistic way supporting the BME hypothesis. For nadir and maximum values of the neutrophil concentrations, a decrease over the cycles was observed, but maximum values were more affected, as supported by the data. The inability of the stem cell compartment to recover within a cycle mimicked the aforementioned BME hypothesis that long-term stem cells are damaged. Note that although proliferation of stem cells was affected by the same drug effect parameter (Edrug=SL•CPTX(t)), the overall toxic effect for each of the two cell types in bone marrow
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-23 -is dependent on the proliferation rate (i.e. kprol•(1-Edrug) and kstem•(1-Edrug)) (Berenbaum, 1972) which is smaller for stem cells compared to progenitor cells (Steinman, 2002) . Hence, stem cells were ultimately assumed to be less susceptible in accordance with literature (Harrison and Lerner, 1991) . Damage of these cells was especially seen for the second and following cytotoxic dose administrations, when due to the haematopoietic stress caused by the first drug administration, the stem cell proliferation was stimulated, thus, being more vulnerable (Harrison and Lerner, 1991; Trumpp et al., 2010) . The BME hypothesis is also supported by the fact that the platelet concentrations showed the same decreasing pattern over time (Supplemental Figure 4) , which is plausible when the stem cells, from which neutrophils and platelets originate, are disturbed. Model C further predicted a long span (approx. half a year after last dose) for the stem cells to fully recover. Since no neutrophil measurements were available for such a long period, the hypothesized long recovery time for the entire bone marrow beyond the 6 th cycle represent extrapolations needing further validation. Unfortunately, this period is typically not monitored even though baseline is not achieved, since the patients rapidly recovery to non-neutropenic grade 0. Nevertheless, a long recovery time seems plausible, since previous chemotherapies have been identified to reduce baseline (Kloft et al., 2006) , supporting the assumption that the bone marrow could still be affected. Model C also showed good agreement of the system-related parameters (MMT and γ) between the original model and literature (Friberg et al., 2002) , indicating that previous knowledge gained from the Friberg et al. model, could be used to inform Model C. Overall, the best description of the neutrophil data was obtained using Model A and Model C. However, Model C integrated the most physiological explanation for the effect and has the potential to describe long-term treatment with paclitaxel.
So far, only the neutropenic effect of paclitaxel had been considered, but combination therapy with cis-/carboplatin, known to have an impact on neutropenia (Go and Adjei, 1999) , was administered.
Differentiation of drug effects was necessary for future simulation, when dose recommendation of paclitaxel and the platinum-based components shall be adapted. Thus, Model C was extended and the platinum combination model assuming additive drug effects slightly improved the model prediction, while allowing for a more realistic drug effect.
The estimated paclitaxel slope in the combination PK/PD model was lower than in Model C, which is reasonable since the drug effect was divided into two components (paclitaxel and platinum-based drugs). Compared to literature, paclitaxel and carboplatin slope factors were approximately 2-fold higher as previously reported for the respective monotherapy (paclitaxel: 2.21 L/µmol (Friberg et al., 2002) , This article has not been copyedited and formatted. The final version may differ from this version.
-24 -1.85 L/µmol ; carboplatin: 0.460 L/mg (Schmitt et al., 2010) ). Deviations point towards a synergistic pharmacodynamic interaction, which is not considered in the additive assumption underlying this model. Synergism has been suggested previously (Choy et al., 1998; Engblom et al., 1999) and is mechanistically plausible: paclitaxel increases the proportion of cells in G1 phase of the cell cycle, where cells become more sensitive to carboplatin (Long and Fairchild, 1994; Engblom et al., 1999) . However, more complex models (e.g. general PD interaction model (Wicha et al., 2016) ) were not supported by the data. Hence, the simplified (additive effect model) was selected, but predictions of neutropenia grade from extrapolated combination drug concentrations should be regarded with care, since the synergistic interaction depends on both drug concentrations. Despite this limitation, the platinum combination model well described the data also from the conventional study arm, indicating good predictive performance.
To conclude, a comprehensive PK/PD model able to describe and predict cumulative neutropenia after paclitaxel combination therapy was developed. Describing this long-term effect semi-mechanistically improved the understanding of neutropenia and gave further evidence of the BME hypothesis that the effect on the pluripotent stem cells might cause cumulative neutropenia. Due to the mechanistic character of the model, the framework can be applied to other myelotoxicity drugs. In addition, the model can differentiate between the paclitaxel and carboplatin effect which allows for better predictions of dose adaptations for patients with non-small cell lung or ovarian cancer. Further data assessment with other doses of the combination therapy as well as neutrophil concentration evolvement after treatment end should be performed. This model showed a high predictive performance for the conventional arm in which no drug concentration had been determined. In this work we used a confirmatory phase IV study not only for assessing the dosing algorithm but also for additional learning, as suggested by (Sheiner et al., 1997) .The developed paclitaxel-carboplatin combination PK/PD model laid the basis for further explorations of different dosing strategies to increase our knowledge and thus to contribute to further individualized anticancer treatment.
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